FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990575169> ?p ?o ?g. }

• W2990575169 endingPage "6560" @default.
• W2990575169 startingPage "6546" @default.
• W2990575169 abstract "// Mar&#x00ED;a Jos&#x00E9; Godoy-Calder&#x00F3;n 1 , 2 , Eglys Gonz&#x00E1;lez-Marcano 1 , 2 , Jeismar Carballo 2 and Ana Federica Convit 1 , 2 1 Unidad Experimental de Inmunoterapia, Fundaci&#x00F3;n Jacinto Convit, Caracas, Venezuela 2 Jacinto Convit World Organization, Inc., Palo Alto, CA, USA Correspondence to: Mar&#x00ED;a Jos&#x00E9; Godoy-Calder&#x00F3;n, email: publicaciones@jacintoconvit.org Keywords: combination immunotherapies; cancer immunotherapy; breast cancer; autologous tumor cells vaccine; anti-PD-1 Received: May 29, 2019     Accepted: September 24, 2019     Published: November 12, 2019 ABSTRACT Breast cancer therapies using checkpoints alone have not been highly effective. Based on previous experiences using the ConvitVax, an autologous tumor cells/bacillus Calmette-Gu&#x00E9;rin (BCG)/formalin-based vaccine, in breast cancer and the potential success of combined therapies, we sought to ascertain whether the ConvitVax combined with anti-PD-1 enhances the antitumor effect in a 4T1 breast cancer model. Animals received four weekly injections of either PBS (G1), ConvitVax (200 &#x03BC;g cell homogenate, 0.0625 mg BCG, 0.02% formalin) (G2), 50 &#x03BC;g anti-PD-1 (G3), or ConvitVax plus anti-PD-1 (200 &#x03BC;g cell homogenate, 0.0625 mg BCG, 0.02% formalin, 50 &#x03BC;g anti-PD-1) (G4). Five weeks post tumor induction all mice were euthanized, tumors extracted and evaluated pathologically and by immunohistochemistry. The combination group (G4) showed 10% more tumor necrosis, greater infiltration of PD-1 &#x002B; cells and lower infiltration of TAMs, evidencing that the combination of ConvitVax and anti-PD-1 can improve the antitumor effect of the vaccine. Using a higher anti-PD-1 dose and administering each treatment at different times could further potentiate the effect of our therapy. Given the vaccine&#x2019;s low cost and simple preparation, its use in combination with checkpoints or other target-specific compounds may lead to a highly effective personalized breast cancer immunotherapy." @default.
• W2990575169 created "2019-12-05" @default.
• W2990575169 creator A5036947807 @default.
• W2990575169 creator A5070466973 @default.
• W2990575169 creator A5079097915 @default.
• W2990575169 creator A5086345129 @default.
• W2990575169 date "2019-11-12" @default.
• W2990575169 modified "2023-09-26" @default.
• W2990575169 title "Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment" @default.
• W2990575169 cites W1979419663 @default.
• W2990575169 cites W1980137951 @default.
• W2990575169 cites W1982488143 @default.
• W2990575169 cites W1984133971 @default.
• W2990575169 cites W1989660541 @default.
• W2990575169 cites W2002380409 @default.
• W2990575169 cites W2032447251 @default.
• W2990575169 cites W2037114269 @default.
• W2990575169 cites W2043871309 @default.
• W2990575169 cites W2047564123 @default.
• W2990575169 cites W2049999948 @default.
• W2990575169 cites W2052313621 @default.
• W2990575169 cites W2055132644 @default.
• W2990575169 cites W2056828743 @default.
• W2990575169 cites W2073300038 @default.
• W2990575169 cites W2086526310 @default.
• W2990575169 cites W2102575291 @default.
• W2990575169 cites W2104347254 @default.
• W2990575169 cites W2112887207 @default.
• W2990575169 cites W2125503103 @default.
• W2990575169 cites W2137018390 @default.
• W2990575169 cites W2146252487 @default.
• W2990575169 cites W2148537942 @default.
• W2990575169 cites W2149121521 @default.
• W2990575169 cites W2150279434 @default.
• W2990575169 cites W2151685029 @default.
• W2990575169 cites W2152897456 @default.
• W2990575169 cites W2155412969 @default.
• W2990575169 cites W2162259611 @default.
• W2990575169 cites W2199953088 @default.
• W2990575169 cites W2281516043 @default.
• W2990575169 cites W2281666530 @default.
• W2990575169 cites W2329696720 @default.
• W2990575169 cites W2345415641 @default.
• W2990575169 cites W2460789061 @default.
• W2990575169 cites W2504606663 @default.
• W2990575169 cites W2524109460 @default.
• W2990575169 cites W2531774921 @default.
• W2990575169 cites W2560367415 @default.
• W2990575169 cites W2572174216 @default.
• W2990575169 cites W2574924315 @default.
• W2990575169 cites W2607369565 @default.
• W2990575169 cites W2735041159 @default.
• W2990575169 cites W2760957546 @default.
• W2990575169 cites W2765452493 @default.
• W2990575169 cites W2772888620 @default.
• W2990575169 cites W2775149708 @default.
• W2990575169 cites W2781227791 @default.
• W2990575169 cites W2785934310 @default.
• W2990575169 cites W2791308824 @default.
• W2990575169 cites W2793228705 @default.
• W2990575169 cites W2793960645 @default.
• W2990575169 cites W2799593746 @default.
• W2990575169 cites W2800405451 @default.
• W2990575169 cites W2897422388 @default.
• W2990575169 cites W2902530914 @default.
• W2990575169 cites W2918171974 @default.
• W2990575169 doi "https://doi.org/10.18632/oncotarget.27283" @default.
• W2990575169 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6859918" @default.
• W2990575169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31762937" @default.
• W2990575169 hasPublicationYear "2019" @default.
• W2990575169 type Work @default.
• W2990575169 sameAs 2990575169 @default.
• W2990575169 citedByCount "2" @default.
• W2990575169 countsByYear W29905751692020 @default.
• W2990575169 countsByYear W29905751692021 @default.
• W2990575169 crossrefType "journal-article" @default.
• W2990575169 hasAuthorship W2990575169A5036947807 @default.
• W2990575169 hasAuthorship W2990575169A5070466973 @default.
• W2990575169 hasAuthorship W2990575169A5079097915 @default.
• W2990575169 hasAuthorship W2990575169A5086345129 @default.
• W2990575169 hasBestOaLocation W29905751691 @default.
• W2990575169 hasConcept C121608353 @default.
• W2990575169 hasConcept C126322002 @default.
• W2990575169 hasConcept C143998085 @default.
• W2990575169 hasConcept C204232928 @default.
• W2990575169 hasConcept C2777701055 @default.
• W2990575169 hasConcept C530470458 @default.
• W2990575169 hasConcept C71924100 @default.
• W2990575169 hasConceptScore W2990575169C121608353 @default.
• W2990575169 hasConceptScore W2990575169C126322002 @default.
• W2990575169 hasConceptScore W2990575169C143998085 @default.
• W2990575169 hasConceptScore W2990575169C204232928 @default.
• W2990575169 hasConceptScore W2990575169C2777701055 @default.
• W2990575169 hasConceptScore W2990575169C530470458 @default.
• W2990575169 hasConceptScore W2990575169C71924100 @default.
• W2990575169 hasIssue "61" @default.
• W2990575169 hasLocation W29905751691 @default.
• W2990575169 hasLocation W29905751692 @default.

• next